Internal Reference Number: FOI_6598
Date Request Received: 19/05/2022 00:00:00
Date Request Replied To: 13/06/2022 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal treatments in Ophthalmology
Request Category: Companies
| Question Number 1: How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition: 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 1: Aflibercept 1657 Bevacizumab 9 Brolucizumab 0 Dexamethasone 14 Ranibizumab 47 | |
| Question Number 2: For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. 鈥� Aflibercept 鈥� Bevacizumab 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 2: Aflibercept 110 Bevacizumab <5 Brolucizumab 0 Dexamethasone 0 Ranibizumab 0 | |
| Question Number 3: Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following: 鈥� Aflibercept 鈥� Bevacizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 3: Aflibercept 190 Bevacizumab 0 Dexamethasone 9 Ranibizumab 0 | |
| Question Number 4: Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following: 鈥� Aflibercept 鈥� Bevacizumab 鈥� Dexamethasone 鈥� Ranibizumab | |
| Answer To Question 4: Aflibercept 236 Bevacizumab 0 Dexamethasone <5 Ranibizumab <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at 黑料网 District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
